Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Emergent BioSolutions Gains on Trial News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:10PM CDT
Emergent BioSolutions is looking to expand BioThrax's label.
Amgen Announces Webcast of 2014 First Quarter Financial Results
PR Newswire - Thu Apr 17, 3:05PM CDT
Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:15 p.m. PDT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Early Glance: Biotechnology companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Midday Glance: Biotechnology companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Google, Disney, Paramount Execs Join Pepperdine University's Talent Management Symposium, April 25
Business Wire - Wed Apr 16, 10:00AM CDT
Human resources and learning officers from leading California employers are among the expert speakers added to the Talent Management Symposium: Leveraging Human Capital program on Friday, April 25, 2014, announced Pepperdine University's Graziadio School of Business and Management. Human resources professionals, organization development leaders and functional managers and supervisors will hear speakers from both the business and the academic worlds discuss the art of attracting, developing, deploying and retaining talent to achieve strategic objectives and meet future business needs.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
FDA Nod for Merck's Grastek - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:11PM CDT
Merck announced that the FDA has approved Grastek, a timothy grass pollen allergen extract.
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.